哺乳动物核移植研究进展

核移植技术具有重大的生物学的意义，特别是体细胞核移植技术的成功表明动物分化的体细胞核可再程序化，哺乳动物核移植的研究虽然还存在许多问题需要解决，但在挽救濒危动物，转基因动物研究，人类器官移植等许多方面展现了广阔的应用前景．     

大鼠肝ADAMs种类鉴定及肝再生过程中ADAMsmRNA差异分析

以 2 / 3肝切除 (patialhepatectomy ,PH)大鼠为材料 ,利用PT -PCR技术 ,通过ADAMs通用引物初步分析了肝脏中ADAMs种类及PH后恢复 4h和 36h时ADAMsmRNA差异。结果表明 :PH后不同恢复时间ADAMsmRNA的扩增谱带没有差异 ,但扩增谱带的强弱有变化 ;cDNA克隆和测序分析表明 ,大鼠肝脏有ADAM15和ADAM 19mRNA同源序列。     

Therapeutic applications of bone marrow-derived stem cells in liver transplantation for end-stage liver diseases

Today, liver transplantation (LT) is the only established treatment for end-stage liver diseases. The de- velopment of LT, including OLT, cadaveric LT, split LT, living donor LT (LDLT), brings hopes to patients with these diseases. However, increasing donor shortage, rejection and life-long immunosuppression with its side effects are the major limitations of this therapy strategy. Bone marrow-derived stem cells (BMDSCs) are capable of differentiating into hepatocyte-like cells and contribute to liver injury repair. The microenvironment of liver injury caused by rejection, ischemia/reperfusion, loss of liver mass, recurrence of HCV and "small-for-size syndrome" after LT can attract a variety of bone marrow-derived stem cell population to the peripheral circulation and then migration to the injury liver to promote the hepatic function restoration. Additionally, BMDSCs can also take part in the functional regeneration of living donor liver after LDLT. This participation in liver regeneration may be associated to the interac- tion between SDF-1and its receptor CXCR4, involving HGF, IL-8, MMP9, and VEGF/VEGFR-2. BMDSC with its bio-characteristics could maintain the allograft tolerance from different angles and in different ways. In conclusion, BMDSCs transplantation, as a new assistant therapeutic method for LT, will ex- pand the space of LT, and provide more survival opportunities for the patients suffering liver diseases in the future.     

醚类汽油添加剂与L-02正常人肝细胞、人血红蛋白的体外作用研究

研究了新型无铅汽油添加剂甲基叔丁基醚（MTBE）、甲基叔戊基醚（TMAE）对正常人肝细胞系L－02的毒性作用，在较高浓度下，MTBE、TAME均对L－02正常人肝细胞的生长有影响，且TAME的毒性作用稍强，另外，用FT－IR法和^1H-NMR法研究了MTBE、TAME与人血红蛋白的体外作用，结果显示，MTBE、TAME与人血红蛋白无明显的直接作用。     

sHLA-I研究进展述评

SHLA-I参与调节免疫应答和诱导免疫耐受，临床上血清sHLA—I水平可作为预测移植预后及妊娠成功与否、反映感染性疾病及某些自身免疫性疾病的活动状态、观察肿瘤分化程度及预后的指标。     

Induction of hemopoietic chimerism in the caprine fetus by intraperitoneal injection of fetal liver cells

Summary Intraperitoneal injection of allogeneic liver cells from 43-day-old male fetuses into normal 60-day female goat fetuses resulted in persistent hemopoietic chimerism in surviving recipients without clinical evidence of graft-versus-host disease. Transplantation of normal fetal liver cells into preimmunocompetent goat fetuses affected with -D-mannosidosis may provide an alternative strategy for evaluating hemopoietic stem cell transplantation in the treatment of human lysosomal storage diseases.     

白芨微球的研制及其肝动脉栓塞实验研究

研究白及微球的制作工艺及其猪肝动脉栓塞和临床患者栓塞的效果。方法：采用乳化－冷凝技术制备白及微球,并通过正交实验,确定制备特定粒径微球的最佳工艺条件。通过股动脉经导管把白及微球注入肝动脉。结果：正交试验结果表明所考察的因素如搅拌速度、油／水比例和白及胶浓度对微球粒径及分布均有显著影响。白及微球呈圆形,粒径分布窄,圆整,分散性好,平均粒径为５４３６μｍ。实验小猪微球栓塞后的肝动脉造影表明白及微球可致肝右支动脉一级、二级分支完全栓塞;病理检查表明梗死区可见肝组织呈肝硬变改变,大量的假小叶形成。微球临床初步应用效果良好。结论：白及微球作为新型肝动脉栓塞制剂在介入栓塞治疗中有较好的作用     

Cyclophosphamide-impaired regulation of hepatic heme metabolism

Summary Im male rats hepatic cytochromes b₅ and P-450 were reduced at different times after treatment with cyclophosphamide (CP) (200 mg/kg i.p. for 3 days). In contrast, microsomal heme did not change until 48 h after the last dose of CP, leading to accumulation of heme in a non-cytochromal form. Parallel to the above changes the heme metabolism showed derangement: -aminolaevulinate synthase, the rate-limiting enzyme in heme synthesis, was depressed and heme oxygenase, the enzyme which catalyzes the oxidative degradation of heme, was increased.     

抗肝纤维化药物研究现状

肝纤维化是肝硬化的早期阶段，是慢性肝病向肝硬化发展的必经途径，也是各种慢性肝病的共同病理过程，因此阻断肝纤维化的发生和发展具有重要意义．所以人们对抗肝纤维药物的研究十分重视．本文将简要综述近年来对肝纤维化药物的一些新认识和新进展．     

无关供者骨髓移植治疗多次复发性急性白血病

文章探讨无关供者骨髓移植治疗多次复发急性白血病的疗效 .经改良 Bucy方案预处理后对一例第三次复发的急粒患者行无关供者骨髓移植 ,同时给防治 GVHD、抗感染治疗 .结果 + 2 1天骨髓在患者体内植活 ,+ 35天细胞染色体分析呈供者型 ( 4 6,XX.正常核型 ) ,+ 84天血型转换成供者型 ,至今已无病生存超过 6个月 .结果表明 ,无关供者骨髓移植对多次复发的急性白血病患者具有治疗价值